Cancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at

Investment analysts at initiated coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Price Performance

Shares of CGIX stock opened at $0.18 on Tuesday. Cancer Genetics has a 1 year low of $2.11 and a 1 year high of $17.50. The business’s 50 day moving average is $0.26. The firm has a market capitalization of $725,291.75, a price-to-earnings ratio of -0.09 and a beta of 2.72.

About Cancer Genetics

(Get Free Report)

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.

See Also

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.